News and Comments

BIOTECHNOLOGY PROMISES A HUGE GROWTH

  Wednesday, December 21, 2011

EXELIXIS’ (EXEL) advanced PI3K-delta research and development preclinical program attracted Merck, known as MSD outside of the United States and Canada. “PI3K-delta is therapeutic target that academic researchers and the drug industry are racing to develop therapeutic antagonists for both inflammatory diseases and cancer. To get to Exelixis program, Merck agreed to pay $12 million in upfront payment in addition to potential milestone payments for multiple indications of up to $239 million and royalties on net-sales of products that would emerge from the agreement. Merck will also pay Exelixis royalties on any compounds that would emerge from Exelixis’ PI3K-delta program or from certain compounds that arise from Merck’s internal discovery efforts targeting PI3K-delta during a certain period. More...


Recent Postings


Archive


Tags

Intermune (ITMN) Jazz Pharmaceuticals (JAZZ) Endometrial Cancer SUNESIS PHARMACEUTICALS (SNSS) ABBVIE (ABBV) Theravance (THRX) Mirati Therapeutics (MRTX) Bristol-Myers Squibb (BMY) MODERNA BIOMARIN (BMRN) Benlysta (belimumab) Rapamune SERES THERAPEUTICS (MCRB) Aimmune Therapeutics (AIMT) KERYX (KERX) Sequenom (SQNM) ADVENTRIX (ANX) ARCA (ABIO) Anadys (ANDS) Amgen (AMGN) INNOVIVA (INVA) Editas (EDIT) NANTKWEST (NK) Auspex (ASPX) HALOZYME (HALO) Zerenex Sanofi (SNY) Genentech AstraZeneca (AZN) Intrexon (XON) REGULUS (RGLS) Advaxis (ADXS) Ocular Therapeutix (OCUL) ARGOS (ARGS) Elan (ELN) PTC Therapeutics (PTCT) Ziofpharm (ZIOP) ACADIA (ACAD) Dendreon (DNDN) Anacor (ANAC) CRISPR Therapeutics (CRSP) Vertex (VRTX) Cytokinetics (CYTK) Telaprevir NOVOCURE (NVCR) Exelixis (EXEL) Onyx (ONXX) Sanofi (SNA) AERIE PHARMACEUTICALS CompuGen (CGEN) Pluristem (PSTI) Biogen Idec (BIIB) Revlimid (lenolidamide) ISIS (ISIS) Micromet (MITI) Intercept (ICPT) Theravance Bio Pharma (TBPH) Gilead (GILD) RenenxBio (RGNX) Abbott Laboratories (ABT) AGOS (ARGS) Agenus (AGEN) OSI (OSIP) Illumina (ILMN) Velcade (bortezomib) Prolor Biotech (PBTH) Multiple Myeloma Dynavax (DVAX) JUNO (JUNO) Idenix (IDIX) Bellicum (BLCM) CEMPRA (CEMP) Sanofi-Aventis (SAN) Ariad (ARIA) Regeneron (REGN) Global Cell Therapeutics (GBT) GlaxoSmithKline (GSK) Ridaforolimus Merck (MRK) Array Pharmaceuticals (ARRY) Human Genome Sciences (HGSI) Trastuzumab-DM1 Sarepta (SRPT) Adaptimmune (ADAP) IDERA (IDRA) C4 Therapeutics TOKAI (TKAOI) ZALTRAP™ ImmunoGen (IMGN) Human Longevity (HLI) Valeant Pharmaceuticals International (VRX) Biocryst (BCRX) NEKTAR (NKTR)) Ionis (IONS) VANDA (VNDA) Alnylam (ALNY) Sangamo (SGMO) Tysabri Herceptin Inovio (INO) Agenus (AGEN Galena (GALE) Roche (ROCHE) Spike Therapeutics (ONCE) Seattle Genetics (SGEN) KITE (KITE) Alder Biopharmaceuticals (ALDR) galapagos (GLPG) Xoma (XOMA) Roche (RHHBY) SYNTA (SNTA) Incyte (INCY) Vitae Pharmaceuticals (VTAE) Prosensa (RNA) GUARDIAN HEALTH